1,2,3-Benzoxathiazine-2,2-dioxides - effective inhibitors of human carbonic anhydrases

J Enzyme Inhib Med Chem. 2023 Dec;38(1):225-238. doi: 10.1080/14756366.2022.2142787.

Abstract

A series of 1,2,3-benzoxathiazine-2,2-dioxides possessing various substituents in the 5, 7, or 8 position was obtained from corresponding 2-hydroxybenzaldehydes in their reaction with sulfamoyl chloride. 5-, 7-, and 8-aryl substituted 1,2,3-benzoxathiazine-2,2-dioxides were prepared from aryl substituted 2-hydroxybenzaldehydes obtained from 3-, 4-, or 6-bromo-2-hydroxybenzaldehydes via two-step protocol. 1,2,3-Benzoxathiazine-2,2-dioxides were investigated for the inhibition of four human carbonic anhydrase (hCA, EC 4.2.1.1) isoforms, cytosolic hCA I and II and tumour-associated transmembrane hCA IX and XII. Twenty four derivatives of 1,2,3-benzoxathiazine 2,2-dioxide were obtained. Most of them act as nanomolar inhibitors of hCA IX and XII. Almost all compounds except 2d and 5a-e also express nanomolar inhibitory activity for hCA II. hCA I is poorly inhibited or not inhibited by 1,2,3-benzoxathiazine 2,2-dioxides. Some of the new derivatives exhibit promising selectivity towards CA IX/XII over hCA I, although none of the compounds are selective towards CA IX/XII over both hCA I and II.

Keywords: 123-benzoxathiazine 22-dioxide; Carbonic anhydrase; inhibitors.

MeSH terms

  • Antigens, Neoplasm
  • Carbonic Anhydrase IX / metabolism
  • Carbonic Anhydrase Inhibitors / pharmacology
  • Carbonic Anhydrases* / metabolism
  • Humans
  • Molecular Structure
  • Neoplasms*
  • Structure-Activity Relationship

Substances

  • Carbonic Anhydrases
  • Carbonic Anhydrase Inhibitors
  • Carbonic Anhydrase IX
  • Antigens, Neoplasm

Grants and funding

The work was supported by the European Regional Development Fund [ERDF, project no. 1.1.1.2/VIAA/3/19/576].